APA Annual Meeting

NEW YORK CITY—The investigational olanzapine-samidorphan drug ALKS 3831 did not outperform olanzapine alone in reducing alcohol use in patients with schizophrenia and alcohol use disorder, but it did improve symptoms of schizophrenia, a study found.


A research team from Florida International University, Miami, analyzed data from 1,004 Hispanic participants ages 18 to 25.

APA President Reneé Binder said there “there are still significant problems with enforcement” of mental health parity laws.

The psychiatric emergency department was the most common site of frequent patient-targeted googling.